One reason for this is the use of various polyclonal antisera, which differ in the extent to which they may recognize some of the multiple forms of osteocalcin in the circulation. In addition to intact osteocalcin, other immunoreactive forms in plasma are a high-molecularmass form (100 kDa) (19, 20) and peptides of lower molecular mass (1000-1500 Da) (21-23).
rate (0.105 mol/L) or lithium hepann gave values 92.4% and 83.6% of those obtained with matched serum samples. Osteocalcin concentrations were relatively stable in plasma and serum at -20 #{176}C for two freeze/thaw cycles. In blood from 100 patients there was a good correlation between osteocalcin concentrations in serum and plasma (lithium heparin) (r2 = 0.831); the slope and intercept (±SE) were 0.924 ± 0.04 and 4.92 ± 1.25 pg/L, respectively. However, in 10 patients, serum osteocalcin concentrations were two-to threefold higher than those in matched plasma samples. Osteocalcin is a bone-specific protein consisting of 49 amino acids, three of which are 'y.carboxyglutamic acid (1). Synthesized by osteoblasts, osteocalcin enters the blood (2) (3) (4) , where its concentration in plasma reflects the rate of bone formation rather than the rate of bone resorption (5). Measurements of plasma osteocalcin are used in various clinical situations, including metabolic bone diseases, hyperthyroidism, liver cirrhosis, renal disorders, and diseases related to excess glucocorticoids (6) (7) (8) (9) (10) (11) (12) 
MaterIals and Methods
Subjects: Plasma and serum were prepared from the same blood samples from two groups of patients (A and B), selected without conscious bias in the outpatient department of University College Hospital. Group A consisted of 20 women, ages 30-60 years, who had no clinical history or symptoms of bone-related disorders or conditions known to influence bone metabolism; one patient with anorexia nervosa was under investigation for osteoporosis. Samples from these subjectswere used for the studies described in Tables 1-3 . Group B consisted of 100 subjects, both men and women: 40, ages 18 were used as controls.
Results

Effect of Different Anticoagulants
Osteocalcin concentrations were lower in plasma than in serum and varied with the anticoagulant used in samples from six patients in Group A (Table 1) . Plasma prepared in the presence of sodium citrate (0.105 molIL) had the highest concentration of immunoreactive osteocalcin, whereas samples with potassium oxalate/sodium fluoride had the lowest (Table 1 ). Blood samples from these patients were kept at 4#{176}C for 24 h before plasma and serum were separated. A similar trend was obtained with serum and plasma from five other patients in Group A when blood was stored at room temperature, -15 #{176}C, for 24 h (Table 2, 
16.6
Bloodsamples from five patients in Group A were incubatedat room temperature (15 #{176}C a Blood from nine patients in Group A was stored at 4#{176}C in lithium hepann for various periods before plasma was separated from blood cells.
Plasma/Serum Correlation
Osteocalcin concentrations, measured by RIA with use of a polyclonal antibody (19), correlated well in matched serum and plasma (lithium heparin) samples from 100 patients from Group B [r2 = 0.831; slope and intercept (±SE), 0.924 (0.04) and 4.92 (1.25) g/L, respectively]. However, in 10 samples from this group, osteocalcin concentrations were two-to threefold higher in serum than in plasma. The latter samples were taken from both controls and patients with osteoporosisand renal impairment. They were of the same age range as the 90 individuals whose matched serum and plasma osteocalcin concentrations were similar. A similar result was obtained when the same samples were reassayed by EIA with use of a monoclonal antibody. The differences between serum and plasma persisted after one freeze/thaw cycle.
DIscussion
These studies showed that plasma osteocalcin values measured by EIA or RIA are influenced by the type of anticoagulants. Osteocalcin concentrations in plasma prepared with potassium oxalate/sodium fluoride were considerably lower than those in matched serum values and decreased further when erythrocytes were allowed in contact with plasma and this anticoagulant for 24 h at 4#{176}C or at room temperature (Tables 1 and 2 ). This might be due to the hydrolysis of osteocalcin by peptide hydrolases released from erythrocytes in the presence of the anticoagulant, as suggested by recent studies (21) . Further evidence for this is also the increased hemolysis seen with potassium oxalate/sodium fluoride compared with other anticoagulants. Peptide hydrolase activity apparently remains active after separation of erythrocytes because osteocalcin concentrations continue to decrease with storage at room temperature (Table 2) . Concentrations decreased faster in the oxalate/fluoride samples, which were also the most hemolyzed.
Osteocalcin values were stable in plasma and serum stored at -20 #{176}C for at least one freeze/thaw cycle but decreased after two cycles. This is probably caused by peptide hycirolase or proteinase activity because pure osteocalcin standards withstand repeated freeze/thaw cycles and are unaffected by heating to 70#{176}C for 15 miii (24). Here no loss of immunoreactivity occurred with storage at 4 #{176}C for seven days. In contrast, fresh serum and plasma samples containing either endogenous human osteocalcin or added bovine osteocalcin decreased by 25% after 24 h at 4#{176}C. After 24 h at 4#{176}C, serum and plasma samples, previously subjected to two freeze/thaw cycles within two months, lost only 10% of the osteocalcin that had been added to them. This is probably attributable to reduction in proteolytic activity as a result of freezing and thawing.
There was a good correlation between osteocalcin concentrations in 100 matched serum and plasma (lithium heparin) samples, in agreement with results from other studies (24, 25) . However, in 10 patients, serum osteocalcin concentrations were two-to threefold those of plasma. This difference persisted when samples were assayed by EIA and RIA and when a polyclonal or a monoclonal antibody was used. We have no explanation for this difference, but it indicates that one should interpret high serum osteocalcin values with caution. We previously noticed that when some serum samples are subjected to gel filtration on a Sephadex G-100 column, an immunoreactive osteocalcinpeak appears at the void volume as well as at the anticipated location (19) . This peak was not present in all samples and may be a contributing factor to this difference between serum and plasma. This peak at the void volume has been reported by another group (20) but not by others (26) . In contrast with a recent report (21), we detected no immunoreactive osteocalcin peaks at the molecular mass region of 1000-1500 Da. This indicates that our antibodies, both monoclonal and polyclonal, do not detect osteocalcin peptides that may be released as a result of the bone resorption process.
We recommend that, for the measurement of osteocalcm concentration in serum or plasma, one should be mindful of the anticoagulant used and should not use oxalate/fluoride. Plasma or serum samples should be stored as soon as possible at -20 or -70 #{176}C, in small volumes. Samples should not be thawed more than twice
